Drawing for INGENEUS THERAPY

USPTO serial 78922929

INGENEUS THERAPY

Reviewed by CopyMark Law Group

Status 603
Filing date
Status date
Registration date
—
Examiner
IM, JEAN H
Law office
TMEG LAW OFFICE 101 - EXAMINING ATTORNEY ASSIGNED

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with INGENEUS THERAPY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

David M. Tener

DAVID M TENER CAESAR, RIVISE, BERNSTEIN, COHEN & POKOT7 PENN CTR 11TH FL 1635 MARKET STPHILADELPHIA, PA 19103UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Diagnostic preparations for clinical or medical laboratory use; Pharmaceutical preparations for the treatment of genetic disordersACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 18, 2008MAB3ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL—
Oct 14, 2008ABN3ABANDONMENT - AFTER EX PARTE APPEAL—
Oct 14, 2008EXPTEXPARTE APPEAL TERMINATED—
Aug 27, 2008EXFBEXPARTE APPEAL DISMISSED - FAILURE TO FILE BRIEF—
Feb 15, 2008GNS1NOTIFICATION OF SUBSEQUENT FINAL EMAILED—
Feb 15, 2008GNSFSUBSEQUENT FINAL EMAILED—
Feb 15, 2008CFRCSUBSEQUENT FINAL REFUSAL WRITTEN—
Jan 28, 2008EXPIEX PARTE APPEAL-INSTITUTED—
Jan 28, 2008JURTJURISDICTION RESTORED TO EXAMINING ATTORNEY—
Jan 28, 2008EXAFEXPARTE APPEAL RECEIVED AT TTAB—
Jan 25, 2008TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 25, 2008TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 24, 2008CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 24, 2008CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 24, 2008ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Jan 24, 2008ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Jul 26, 2007GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Jul 26, 2007GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jul 26, 2007CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 11, 2007TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 11, 2007CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 11, 2007TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 9, 2006GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 9, 2006CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 5, 2006DOCKASSIGNED TO EXAMINER—
Jul 11, 2006NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance